3D NEONET SIGNED
Drug Discovery and Delivery NEtwork for ONcology and Eye Therapeutics
Total Cost €
0EC-Contrib. €
0Partnership
0Views
03D NEONET project word cloud
Explore the words cloud of the 3D NEONET project. It provides you a very rough idea of what is the project "3D NEONET" about.
Project "3D NEONET" data sheet
The following table provides information about the project.
| Coordinator |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Organization address contact info |
| Coordinator Country | Ireland [IE] |
| Project website | http://www.3dneonet.org |
| Total cost | 945˙000 € |
| EC max contribution | 945˙000 € (100%) |
| Programme |
1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge) |
| Code Call | H2020-MSCA-RISE-2016 |
| Funding Scheme | MSCA-RISE |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-01-01 to 2020-12-31 |
Partnership
Take a look of project's partnership.
Map
Project objective
Severe ocular disorders are affecting the lives of more than 100Mill people world-wide and at least 25% of the population above 70 years of age, a growing demographic group in EU. More than 8 million people lose their lives to cancer every year, making cancer a leading cause of pre-mature mortality in the world. The main hallmarks of severe eye conditions (i.e angiogenesis, inflammation and vascular permeability) play also pivotal roles in cancer, being therapeutic targets to treat both kind of diseases.
The overall goal of 3D-NEONET is the improvement of available treatments for cancer and ocular disease by enhancing drug discovery-development and delivery to targeted tissues, through advanced international co-operation between academic and non-academic partners. The interdisciplinary expertise provided by 18 partners in 7 countries encompasses among others: drug screens, ADME, toxicology, preclinical models, nanotechnology, biomaterials and clinical trials.
After the success with ongoing FP7-IAPP project 3D-NET (Drug Discovery and Development of Novel Eye Therapeutics; (www.ucd.ie/3dnet), we are assembling 3D-NEONET, this enlarged European interdisciplinary consortium that will join forces and exchange skills to enhance current therapies in oncology and ophthalmology. The 3 global objectives of 3D-NEONET are: 1- Enhance the discovery and development of novel drugs, targets and biomarkers for ophthalmology and oncology. 2- Improve the Delivery of Therapeutics for Oncology and Ophthalmology 3- Enhancement of Research, Commercial and Clinical Trial Project Management Practices in these fields.
Through participation in the program, 3D-NEONET is the vehicle for driving synergies between academic and non-academic partners leading to increased scientific and technological excellence as well as tangible innovative outputs that will strengthen the competitiveness of both the researchers and industries of the network even beyond the lifetime of the network.
Deliverables
| Exploitation of Fungal Resources in Drug Discovery and Drug Metabolism Report | Documents, reports | 2020-03-11 15:21:19 |
| DMP | Open Research Data Pilot | 2020-03-11 15:21:19 |
| Launch of 3D-NEONET Website and Social Media | Websites, patent fillings, videos etc. | 2020-03-11 15:21:19 |
| Initiation of 3D-NEONET Secondments | Other | 2020-03-11 15:21:19 |
| 3D-animations to enhance awareness (Cancer and Blindness) | Websites, patent fillings, videos etc. | 2020-01-14 15:13:29 |
Take a look to the deliverables list in detail: detailed list of 3D NEONET deliverables.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
Nils Ohnesorge, Temitope Sasore, Daniel Hillary, Yolanda Alvarez, Michelle Carey, Breandán N. Kennedy Orthogonal Drug Pooling Enhances Phenotype-Based Discovery of Ocular Antiangiogenic Drugs in Zebrafish Larvae published pages: , ISSN: 1663-9812, DOI: 10.3389/fphar.2019.00508 |
Frontiers in Pharmacology 10 | 2020-03-11 |
| 2018 |
Rebecca Ward, Husvinee Sundaramurthi, Valeria Di Giacomo, Breandán N. Kennedy Enhancing Understanding of the Visual Cycle by Applying CRISPR/Cas9 Gene Editing in Zebrafish published pages: http://hdl.handl, ISSN: 2296-634X, DOI: 10.3389/fcell.2018.00037 |
Frontiers in Cell and Developmental Biology 6 | 2020-03-11 |
| 2018 |
K. Slater, P. S. Hoo, A. M. Buckley, J. M. Piulats, A. Villanueva, A. Portela, B. N. Kennedy Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma published pages: , ISSN: 0167-7659, DOI: 10.1007/s10555-018-9751-z |
Cancer and Metastasis Reviews | 2020-03-11 |
| 2019 |
Rebecca Ward, Zaheer Ali, Kayleigh Slater, Alison L. Reynolds, Lasse D. Jensen, Breandán N. Kennedy Pharmacological restoration of visual function in a zebrafish model of von-Hippel Lindau disease published pages: , ISSN: 0012-1606, DOI: 10.1016/j.ydbio.2019.02.008 |
Developmental Biology | 2020-03-11 |
| 2019 |
BreandánN Kennedy, Andrea Cerquone Perpetuini, Justine Mathoux The potential of small molecule brain-derived neurotrophic factor: mimetics to treat inherited retinal degeneration published pages: 85, ISSN: 1673-5374, DOI: 10.4103/1673-5374.243711 |
Neural Regeneration Research 14/1 | 2020-03-11 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "3D NEONET" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "3D NEONET" are provided by the European Opendata Portal: CORDIS opendata.